Brief: CStone Pharmaceuticals Announces Acceptance Of Marketing Authorization Application By UK MHRA
19/12/2022 13:20
Dec 19 (Reuters) - CStone Pharmaceuticals 2616.HK :
* ACCEPTANCE OF MARKETING AUTHORIZATION APPLICATION BY UK
MHRA FOR
SUGEMALIMAB IN METASTATIC NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nHKS15khrN
Further company coverage: 2616.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on CStone Pharmaceuticals
See all newsBrief: CStone Pharmaceuticals Says CEO Purchases 496,000 Shares For Over HK$2.7 Million From Sept 17-22
Brief: CStone Pharmaceuticals Posts HY Loss Of Rmb252.3 Million
China's CStone Pharmaceuticals H1 revenue soars on drug sales
Brief: Cstone Pharmaceuticals Receives NMPA IND Approval For CS5007 In China
Brief: CStone Pharmaceuticals Says Directors And Senior Management Purchase 2.4 Million Shares In June 2026